glp 1 glp 2 dual agonist Schematic illustration of monoagonists, agonists and triple Review Article: GLP‐1 Receptor Agonists

In small proof-of-concept phase 2 randomized controlled trials (RCTs) in patients with biopsy-confirmed MASH, liraglutide at 1.8 mg/day for 48 weeks (201), semaglutide at 0.4 mg/day for 72 weeks (202), and tirzepatide at 15 mg/week for 52 weeks (203) have been reported to achieve placebo-corrected percentages of participants meeting the criteria for resolution of MASH without worsening fibrosis by 30% (P = 0.019), 42% (P 10%) may lead to diabetes remission (237)

But like all peptides, its powerful stuff and should be treated like a medical treatment, not a casual shortcut

Aging 22 , 195207 (2001)

The C-terminus is a primary carboxamide (-NH), not a free carboxylate

has received consultancy and/or lecture fees from companies with an interest in developing and marketing incretin-based therapies for treatment of type 2 diabetes mellitus (Boehringer Ingelheim, Lilly, Merck/MSD and Novo Nordisk)

Furthermore, it accelerates the healing of skin wounds